BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Integrated molecular genetic profiling of pediatric-high grade gliomas reveals key differences with adult disease

Dataset: Integrated molecular genetic profiling of pediatric-high grade gliomas reveals key differences with adult disease

Purpose: To define copy number alterations and gene expression signatures underlying pediatric high-grade glioma (HGG). Patients and...

Registered by ArrayExpress Uploader
View Dataset

Purpose: To define copy number alterations and gene expression signatures underlying pediatric high-grade glioma (HGG). Patients and Methods: We conducted a high-resolution analysis of genomic imbalances in 78 de novo pediatric HGG, including 7 diffuse intrinsic pontine gliomas, and 10 HGG cases arising in children who received cranial irradiation for a previous cancer, using Affymetrix 500K GeneChips. Gene expression signatures for 53 tumors were analyzed with Affymetrix U133v2 arrays. Results were compared with publicly available data from adult tumors. Results: Pediatric and adult glioblastoma were clearly distinguished by frequent gain of chromosome 1q (30% vs 9%) and lower frequency of chromosome 7 gain (13% vs 74%), respectively. The most common focal amplifications also differed, with PDGFRA and EGFR predominant in childhood and adult populations respectively. These common alterations in pediatric HGG were detected at higher frequency in irradiation-induced tumors, suggesting that these are initiating events in childhood gliomagenesis. CDKN2A was the most common tumor suppressor gene targeted by homozygous deletion in pediatric HGG. No IDH1 hotspot mutations were found in pediatric tumors, highlighting molecular differences in pathogenesis between childhood HGG and adult secondary glioblastoma. Integrated copy number and gene expression data indicated that deregulated PDGFRA signaling plays a major role in pediatric HGG. Conclusions: Integrated molecular profiling showed substantial differences in the molecular features underlying pediatric and adult HGG, indicating that findings in adult tumors cannot be simply extrapolated to younger patients. PDGFRA may be a useful target for pediatric HGG including diffuse pontine gliomas. Keywords: disease state analysis 78 samples for SNP analysis, including 10 samples arising in children who received cranial irradiation for a previous cancer and 7 diffuse pontine gliomas; 53 of them with gene expression analysis; 2 tumor grades To have access to SNP CEL files, please contact Dr. Suzanne Baker (suzzane.baker@stjude.org).

Species:
human

Samples:
53

Source:
E-GEOD-19578

Updated:
Dec.12, 2014

Registered:
Sep.15, 2014


Factors: (via ArrayExpress)
Sample AGE OTHER DISEASE
GSM487990 5.8 years not specified Glioblastoma
GSM48799 16.5 years not specified Glioblastoma
GSM487992 6.3 years not specified Glioblastoma
GSM48799 16.5 years not specified Glioblastoma
GSM487994 17.8 years not specified Glioblastoma
GSM487995 7 years not specified Glioblastoma
GSM487996 13.8 years Post-ALL Glioblastoma
GSM487997 9.9 years not specified Glioblastoma
GSM487998 19.8 years Post-ALL Glioblastoma
GSM487999 9.7 years Post-ALL Glioblastoma
GSM488000 19.8 years Post-Germinoma Glioblastoma
GSM48800 1.2 years not specified Glioblastoma
GSM488002 1 month years not specified Glioblastoma
GSM488003 7.3 years Diffuse pontine glioma Glioblastoma
GSM488004 10.9 years not specified Glioblastoma
GSM488005 4.7 years not specified Glioblastoma
GSM488006 14.3 years not specified Glioblastoma
GSM488007 14.08 years not specified Glioblastoma
GSM488008 4 years Diffuse pontine glioma Glioblastoma
GSM488009 1 years not specified Glioblastoma
GSM488010 10 years not specified Glioblastoma
GSM4880 11.25 years not specified Glioblastoma
GSM488012 3 years not specified Glioblastoma
GSM488013 19 years not specified Glioblastoma
GSM488014 14 years not specified Glioblastoma
GSM488015 12 years not specified Glioblastoma
GSM488016 8.9 years Post-Ependymoma Glioblastoma
GSM488017 13.1 years not specified Glioblastoma
GSM488018 3.8 years not specified Glioblastoma
GSM488019 14.8 years not specified Glioblastoma
GSM488020 10.7 years not specified Glioblastoma
GSM48802 13.1 years Post-medulloblastoma Glioblastoma
GSM488022 13.5 years not specified Glioblastoma
GSM488023 3.6 years not specified Glioblastoma variant
GSM488024 9.2 years Post-ALL Glioblastoma variant
GSM488025 8 years not specified Glioblastoma variant
GSM488026 14.3 years not specified Glioblastoma variant
GSM488027 7.5 years not specified anaplastic astrocytoma
GSM488028 5 days old not specified anaplastic astrocytoma
GSM488029 2.75 years not specified anaplastic astrocytoma
GSM488030 2 years not specified anaplastic astrocytoma
GSM48803 6 years not specified anaplastic astrocytoma
GSM488032 23 years Post-ALL anaplastic astrocytoma
GSM488033 12 years not specified anaplastic astrocytoma
GSM488034 5 years not specified anaplastic astrocytoma
GSM488035 9 years not specified anaplastic astrocytoma
GSM488036 16.7 years Post-ALL anaplastic oligodendroglioma
GSM488037 22.7 years not specified anaplastic oligodendroglioma
GSM488038 10.7 years not specified anaplastic oligodendroglioma
GSM488039 1.6 years not specified anaplastic oligodendroglioma
GSM488040 6.2 years not specified anaplastic oligodendroglioma
GSM48804 7 years not specified Anaplastic PXA
GSM488042 19 years not specified Anaplastic PXA

Tags

  • cancer
  • chromosome
  • cranial
  • disease
  • glioma

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2019 The Scripps Research Institute. All rights reserved. (ver 59fce91 )
  • Terms of Use